000239391 000__ 01514cam\a2200337Ia\45e0
000239391 001__ 239391
000239391 005__ 20220217104435.0
000239391 007__ he\bmb024bbca
000239391 008__ 980916s1995\\\\mdua\\\\b\\\\f000\0\eng\d
000239391 035__ $$a(OCoLC)ocm39877071
000239391 035__ $$a239391
000239391 040__ $$aGPO$$cGPO$$dISE
000239391 043__ $$an-us---
000239391 049__ $$aISEA
000239391 074__ $$a0512-A-37 (MF)
000239391 0860_ $$aHE 22.19/9:D 84
000239391 24500 $$aImpact of the Medicaid drug rebate program$$h[microform].
000239391 260__ $$aBaltimore, Md. :$$bU.S. Dept. of Health and Human Services, Health Care Financing Administration, Office of Research and Demonstrations,$$c[1995]
000239391 300__ $$a43 p. :$$bill.
000239391 440_0 $$aHealth care financing.$$pExtramural research report
000239391 500__ $$aShipping list no.: 98-0809-M.
000239391 500__ $$a"August 1995."
000239391 500__ $$a"Financed by the Health Care Financing Administration under contract number 500-92-0022 and prepared by the Institute for Health Services Research at the University of Minnesota"--T.p. verso.
000239391 533__ $$aMicrofiche.$$b[Washington, D.C.] :$$cSupt. of Docs., U.S. G.P.O.,$$d[1998]$$e1 microfiche : negative.
000239391 650_0 $$aMedicaid.
000239391 650_0 $$aPharmaceutical policy$$zUnited States.
000239391 650_0 $$aDrugs$$xPrices$$xGovernment policy$$zUnited States.
000239391 650_0 $$aPharmaceutical industry$$xGovernment policy$$zUnited States.
000239391 7101_ $$aUnited States.$$bHealth Care Financing Administration.$$bOffice of Research and Demonstrations.
000239391 7102_ $$aUniversity of Minnesota.$$bInstitute for Health Services Research.
000239391 85230 $$bdfich$$hHE 22.19/9:$$iD 84
000239391 909CO $$ooai:library.usi.edu:239391$$pGLOBAL_SET
000239391 980__ $$aBIB
000239391 980__ $$aGOV RESOURCE
000239391 994__ $$aE0$$bISE